Prothena: Switching From ”Hold” To ”Buy” On Lead Alzheimer”s Drug Promise

Thursday, 21 September 2023, 19:39:18
Prothena has lucrative development partnerships with Roche, Novartis, and Bristol Myers Squibb. Click here to see why I am upgrading PRTA stock from Hold to Buy.
— Seeking Alpha

Novartis: fin de l”accord de collaboration avec BeiGene

Wednesday, 20 September 2023, 16:09:00
(CercleFinance.com) – Novartis et BeiGene ont convenu de mettre fin à leur accord de collaboration et de licence pour le tislelizumab, un anticorps monoclonal IgG4 humanisé anti-PD-1 – 20/09/2023 à 16:09 – Boursorama
— Boursorama

Novartis cancels Beigene partnership as cancer drug gains EU approval

Tuesday, 19 September 2023, 23:39:13
… -treat cancers like melanoma and lung cancer , which could make it tough … BeiGene has sole rights, in lung cancer , lymphoma and other indications. Novartis … project recently showed promise in lung cancer . Following news of the deal …
— EIN News Lung Cancer

Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact

Tuesday, 19 September 2023, 15:18:52
BeiGene Ltd (NASDAQ: BGNE ) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS ). Under the agreement signed in 2021, the companies were jointly developing the drug tislelizumab. BeiGene has launched more than 20 potentially registration-enabling trials with Tevimbra, of which 10 Phase 3 trials and four Phase 2 trials have a lready had positive readouts . Minutes later, BeiGene said … Full story available on Benzinga.com
— Benzinga

BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab) | BGNE Stock News

Tuesday, 19 September 2023, 13:00:00
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide.
— Stock Titan